High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. - Wikidata - awgldk - TriplyDB

High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.

High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.

http://www.wikidata.org/entity/Q37336440

about

Antibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral Responses Human antibody response to dengue virus: implications for dengue vaccine design Recent advances in understanding dengue The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response How antibodies alter the cell entry pathway of dengue virus particles in macrophages Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin America Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop.Dissecting the human serum antibody response to secondary dengue virus infections Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination.A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development.Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys.Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.Broad and strong: the ultimate antibody to dengue virus.Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III.Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus.Immune Response to Dengue and Zika.Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.Potent Neutralization Ability of a Human Monoclonal Antibody Against Serotype 1 Dengue Virus.T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and Zika Viruses

P2860

Q25708015-DE530A3F-A449-4BB2-882D-711B0F650A2D Q26314609-CE178A99-82CC-4425-B1F2-42998DA57537 Q26766156-F6657F2B-C0AB-4269-B915-730BFCB47E2B Q26995782-E0ED4D66-B88A-4A48-BDFA-BF3C7DB0061A Q27334575-86E5F30A-A265-48E6-99B5-554C22E4D5EA Q27468944-88492677-D1BB-4EFF-8A55-3F4F5A5DDDAA Q33638496-A57C6445-4FF6-40DD-BFEA-F6E05E328880 Q33728716-8A581166-AA0B-43EC-B0F5-21F4C9AA8485 Q34262245-03DF660A-17D5-4FE6-B70B-7861498831CA Q34386384-CC05F708-B457-43CA-999E-9B8E11BA9DDC Q34594111-9431898E-9EB6-4D54-928D-0D08DB0F911B Q35654743-EF44A09A-1AA5-4DAF-B2B3-C20E079B3F12 Q35758626-028B069D-8336-465D-A967-079E8695F094 Q36950883-19B50C4D-2BCF-46E3-8349-4933BA51E288 Q38636217-CC3004E7-5CCE-4A3D-A9CB-39AB708406E7 Q39535403-865A6C67-7B6A-40B8-BFC1-7DF31E4BE1AA Q40040450-A3045AC4-58E3-4BBE-8DE2-34369CF5824A Q40045875-B3DF15FF-42FC-4E9B-B404-2718520C9760 Q40047887-90A46D73-17A3-4CC0-B375-79540C566100 Q40173610-1BF4E2C9-9BC3-4840-89B2-0A45D75C799B Q41919737-C247EA87-70AD-4593-A0A5-AAB3947C51DC Q42985743-878EF47D-BAD1-4895-83C5-B6A72192282B Q47156413-F9E7AC74-6EFE-43C6-A9F7-70FB09F1C466 Q47551925-24926DAD-604F-41B6-8464-BBA43ABDF89F Q50099498-6746212F-B7A9-4920-BF10-FA8DB67C7F56 Q55338916-0C8707FE-C981-490F-A85C-AC2417E60772 Q56341655-566644E2-AC91-40DC-9663-8530A6C27D04

P2860

High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.

http://www.wikidata.org/entity/Q37336440

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

High-avidity and potently neut ...... ondary dengue virus infection.

@en

High-avidity and potently neut ...... ondary dengue virus infection.

@nl

type

label

High-avidity and potently neut ...... ondary dengue virus infection.

@en

High-avidity and potently neut ...... ondary dengue virus infection.

@nl

prefLabel

High-avidity and potently neut ...... ondary dengue virus infection.

@en

High-avidity and potently neut ...... ondary dengue virus infection.

@nl

P1433

Q37336440-148C0ED6-CFE0-492F-BE10-71288B7E8E44

P1476

Q37336440-D67F47A6-2CB9-425F-832B-2E7022F60F7D

P2093

Q37336440-516CEC1F-3074-4B0F-BCDB-F98289406B86

Q37336440-60D69CD3-E809-49B0-9039-D4BA23AF09AF

Q37336440-7CC5B93A-1FC8-4310-BCF9-39869EE859D5

Q37336440-89D01110-06DF-4528-A22B-232F73369762

Q37336440-9016E516-FAE6-4790-8AD9-45195D90034E

Q37336440-B2715B57-5294-488A-98DA-CBBD9477550D

Q37336440-C6B0F74B-BF9E-432B-8C6F-8D94F962D9AF

P2860

Q37336440-0229C960-0D19-4BD4-9997-3E422934089B

Q37336440-0589D265-0191-4B0D-8A1B-32F081981962

Q37336440-1F0BBC4E-E758-42AA-9121-D735D3682334

Q37336440-200FA331-C484-4DFF-9821-36A14FB5AE89

Q37336440-203DCC66-8D3C-47C3-8D8F-30D22D3910F0

Q37336440-240BA405-1961-4E77-9F93-3036259E62FE

Q37336440-279BA2BA-931E-4321-BDB4-B3558959649F

Q37336440-2C9E0104-0EF4-4821-AE37-1BF4470E5DBE

Q37336440-34E18A8E-BC89-4A6D-8632-770B4852A675

Q37336440-41678A9B-15FD-4F48-9DAC-FDF14BC331C6

P304

Q37336440-470373AB-61B5-4450-BCA3-D7BCA9DC8844

P31

Q37336440-2FA32231-9B04-4ECC-9BCB-1330D13A81C6

P356

Q37336440-E88B0DCC-0836-403C-B277-90C08F833081

P407

Q37336440-886405B6-1DED-477B-ABDD-A10D33F25DC7

P433

Q37336440-A7C80D7C-7494-4F92-BBAD-14C08C12C4D9

P478

Q37336440-F3DAAEFC-9DC3-42CD-96E5-4B87EF7939C4

P50

Q37336440-78CE2463-1B4A-4308-B774-86F483CCF8A4

Q37336440-C769DB69-EE4B-48DE-8C8E-1109F5F996D4

Q37336440-CD5BBB9E-F7E1-4FC9-A335-DC98CC91997D

Q37336440-D208F496-A3F4-4D55-BFB7-8039E8C59105

P577

Q37336440-B7F525F8-797F-47BD-8738-6F46BD3CEA19

P698

Q37336440-5F307A71-E809-40C9-AAF2-02A195F39150

P921

Q37336440-120A806A-5984-4D01-BA75-34FC15E4B728

Q37336440-C725430F-2167-4A3C-9606-0C31D493931C

P932

Q37336440-9A0498A8-13E1-4093-ACF9-BF8E5C98B718

P356

P1433

Journal of Virology

P1476

High-avidity and potently neut ...... ondary dengue virus infection.

@en

P2093

Amonrat Jumnainsong

http://www.w3.org/2001/XMLSchema#string

Carolyn Edwards

http://www.w3.org/2001/XMLSchema#string

Chih-Yun Lai

http://www.w3.org/2001/XMLSchema#string

Hong-En Lin

http://www.w3.org/2001/XMLSchema#string

Scott Halstead

http://www.w3.org/2001/XMLSchema#string

Srisakul Kliks

http://www.w3.org/2001/XMLSchema#string

Yi-Chieh Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion

Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells

Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes

Humanized Monoclonal Antibodies Derived from Chimpanzee Fabs Protect against Japanese Encephalitis Virus In Vitro and In Vivo

Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II

The structural immunology of antibody protection against West Nile virus

Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens

A Therapeutic Antibody against West Nile Virus Neutralizes Infection by Blocking Fusion within Endosomes

Human Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment Step

P304

12562-12575

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.00871-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P50

Gavin R Screaton

Juthathip Mongkolsapaya

P577

2013-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24027331

http://www.w3.org/2001/XMLSchema#string

P921

P932

3838129

http://www.w3.org/2001/XMLSchema#string